The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The role of measuring MRD in CLL
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, describes using minimal residual disease (MRD) monitoring in treating chronic lymphocytic leukemia (CLL). Measuring MRD levels can enable accurate assessment of patients responses to treatment and can accordingly adjust treatment levels. MRD monitoring can additionally predict outcomes to chemoimmunotherapy and certain targeted therapies and Dr Niemann emphasizes the need to create MRD-guided regiments as in the Phase II HOVON-141/VISION trial (NCT03226301). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
